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mice (WT BM cells intoWT recipients), suggesting the role of
host parenchymal tissue cell expression of B7H1 in cGVHD.
Taken together, the PD-1 axis, especially B7H1 expression on
recipients, regulates the frequency of IL-17+ IFNg+ T cells and
contributes to the pathogenesis of cGVHD.433
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Between September 2010 and June 2012, 15 patients with
SAA underwent HLA identical sibling donor SCT using Flu-
darabine 180 mg/m2 IV over 6 days and Cyclophosphamide
100 mg/kg IV over 2 days. Five patients had in addition
a single fraction of Total Body irradiation (TBI) 200 cGy.
Cyclophosphamide 50 mg/kg/day IV on day +3 and +4 was
the sole GVHD prophylaxis. G-CSF mobilized peripheral
blood stem cells (PBSC) was the graft source. Tenmales and 5
females with a median age of 25 years (range: 8 e 42) had
SCT. Median PBSC cell dose infused was 9.5 x 106 CD34/Kg
(range: 5.4 e 17.2). Thirteen engrafted (86.6%) with median
neutrophil and platelet engraftment of 15.4 days (range: 15-
17) and 16.6 days (range: 12-32) respectively. Grade IIeIV
GVHD seen in 3 patients (23%) at 42, 49 and 68 days post SCT.
Two responded to combination of cyclosporine and pred-
nisolone while one patient with grade IV GVHD expired 64
days post SCT. Of 11 evaluable patients, 4 (36.3%) developed
chronic GVHDwhich was limited in all. Two patients with de
novo chronic GVHD were managed with prednisolone alone.
Overall 7 patients (46.6%) have not required any immuno-
suppression after SCT while 3 have required immunosup-
pressive therapy for 114, 127 and 225 days respectively At
a median follow up of 11 months (range: 1 e 22), 11 (73.3%)
are alive and well including 7 patients who did not require
any immunosuppressive therapy following SCT. The use of
post transplant cyclophosphamide as GVHD prophylaxis
following sibling donor transplant for SAA is associated with
low rates of GVHD. A large number (46%) did not require any
immunosuppression post SCT. Larger studies are required to
understand the utility of this prophylaxis in sibling donor
transplants for aplastic anemia.434
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San Francsico, CAPersistence of mixed chimerism (MC) following myeloa-
blative HCT in pediatric hematologic malignancies is related
to a high risk of relapse. We initiated a prospective study of
FWI and DLI in patients with MC at 30 days post-transplant.
We are reporting preliminary results on 43 enrolled patients
with a mean age of 106.5(SD) years. Fifty-eight percent of
patients had myeloid malignancies, 40% lymphoid malig-
nancies and 2% had biphenotypic leukemia. Based on day +30
bone marrow and peripheral blood chimerism results, 26/43
(60%) patients were found to have MC, and were assigned to
the intervention arm of the study consisting of FWI and DLI;
12 patients (28%) had full donor chimerism (FDC) or early
graft-versus host disease (GVHD) and were assigned to
observation arm, and 5 (12%) could not be assigned to either
arm due to early death or relapse. FWI started at a median of
day +50 (range 40-85), and ended at a median of day +75.5
(range 49-113). Following FWI, 9 patients (35%) converted to
FDC. Of 17 patients who remained MC following FWI, 15
proceeded to DLI, 1 did not receive further intervention due
to GVHD and one relapsed prior to DLI. Acute GVHD devel-
oped in 3/26 (12%) patients undergoing FWI and in 9/12
(75%) of patients in the observation arm (P < .01). Two
patients undergoing intervention developed grade II aGVHD
which resolved and 1 developed grade IV aGVHD that pro-
gressed to fatal cGVHD of the lungs. In the observation arm, 2
patients developed grade I, 5 developed grade II, 2 developed
grade III, and 1 developed grade IV aGVHD. Chronic GVHD
developed in 6 patients (2 in the intervention and 4 in the
observation arm). One of 6 patients developed de novo
cGVHD, following DLI. The incidence of acute and/or chronic
GVHD was 15% in the intervention arm of the study. Toxic
death rate due to GVHD was 4%. There were 11 events (3
treatment-related deaths and 8 relapses). Mean follow-up of
living patients was 17.610 (SD) months. EFS for the entire
cohort was 717(SD)% and was not signiﬁcantly different
between the observation arm and the intervention arm. Ten
patients (23%) had evidence of disease by ﬂow or cytoge-
netics, at the time of HCT. Based on chimerism results, 4 were
assigned to the intervention arm, 3 to the observation arm,
and 3 could not be assigned to any arm of the study due to
early relapse or death. EFS was signiﬁcantly lower in patients
with positive disease prior to transplant than in those
without evidence of disease (EFS 2715% vs. 867%). Among
26 patients undergoing intervention, relapse was signiﬁ-
cantly more common (P ¼ .014) in patients with positive
disease pre-transplant. Our data indicate that post-trans-
plant immunomodulation is safe and has overall low GVHD
risk (15%). Our schedule of FWI was not adequate to prevent
relapse in patients coming to transplant with persistent
disease. We would recommend an earlier, (day 30) and more
aggressive schedule of immunosuppression withdrawal for
these patients.435
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Background: GVHD is still a major obstacle in allogeneic
transplantation despite the progress of immunosuppressive
drugs and cell therapy such as mesenchymal stem cells.





Day 28 CR 48% 81% 65%
CR+VGPR 82% 66% 74%
Day 56 CR 64% 82% 73%
CR+VGPR 83% 74% 78%
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autoimmunity (GVA), on the other hand, is suggested from
the fact that autoimmune diseases are ameliorated by allo-
geneic transplantation for accompanying hematologic
disorder. GVHD can be thought as a typical autoimmune
disease caused by donor T cells. From an experience of the
autologous (recipient cells) transplantation for severe GVHD,
which resulted in successful control of GVHD, but disease
relapse probably due to cancelling the GVL effect, we have
pursued the possibility of rescue transplantation from
another donor for refractory acute GVHD in a murine model
and in a clinical trial.
Methods: In a murine GVHD model of BDF1 (H-2b/d) to
B6C3F1 (H-2b/k), GVHD mice underwent a second BMT from
B6B10F1 (H-2b/s) following low-dose TBI 2-3 weeks after ﬁrst
BMT. In a clinical trial, 16 patients who developed severe
acute GVHD, refractory to three to ﬁve lines of GVHD-speciﬁc
treatments, underwent allogeneic stem cell transplantation
using reduced-intensity conditioning regimens with grafts
from a second donor.
Results: In the murine model, GVHD could be successfully
treated by a second BMT. For successful treatment of GVHD,
rapid achievement of full second-donor chimerism was
required. The mice were relatively resistant to new devel-
opment of GVHD by second-donor grafts. The timing of the
second BMT, the intensity of conditioning, and donor selec-
tion could be important. In the clinical trial, among 15
transplantations that could be evaluated, rescue donor grafts
were engrafted in 11 cases and rejected in 4 cases. For
patients who achieved rescue donor engraftment, the
response rate was 90% (CR 8, PR 2, stable 1). 6 of 8 patients
with CR survived without GVHD symptoms, with a median
follow-up of 5.8 years. No new development of GVHD by the
second graft was observed. In contrast, no long-term survi-
vors were observed in patients who rejected rescue donor
grafts.
Conclusions: GVHD could be treated by transplantation
using second donor graft, which eliminates ﬁrst donor
lymphocytes in the murine model and the clinical trial. We
would like to propose the concept of Graft-versus-GVHD, on
the analogy of GVA.436
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Background: We evaluated short-term response endpoints
for clinical trials testing initial treatment of acute graft-
versus-host disease (GVHD). We postulated that the deﬁni-
tion of response should include a reduced symptom burden
and improved failure-free survival (FFS), with failure deﬁned
as death, recurrent malignancy or initiation of second-line
systemic treatment. We also postulated that the response
endpoint should include an upper limit of the steroid dose at
the time of assessment.
Methods: In a cohort of 227 adult patients who received
initial systemic steroid treatment for grades IIB-IV acute
GVHD between 2000 and 2005, treatment response was
evaluated at days 28 and 56 after starting treatment. Stan-
dard deﬁnitions were used to deﬁne complete response (CR)
and traditional partial response (PR). Very good partial
response (VGPR) was deﬁned as a subcategory of traditional
PR when patients had minor rash, minor elevations of totalserum bilirubin or minor gastrointestinal symptoms but
otherwise met criteria for CR (2009 Joint Statement, BBMT).
Sensitivity and speciﬁcity analyses were used to evaluate
each response deﬁnition in predicting FFS at 6 months after
initial treatment. Averages of sensitivity and speciﬁcity were
used to evaluate the trade-off between sensitivity and
speciﬁcity.
Results: Response rates were 33% CR, 24% VGPR and 10%
other PR at day 28, and 40% CR, 14% VGPR and 7% other PR at
day 56. Residual symptom burden at days 28 and 56 after
treatment was lower in patients with VGPR than in those
with other PR, indicating that VGPR is preferred over tradi-
tional PR. In evaluating day 28 and day 56 response endpoints
as predictors of FFS at 6 months, loss of sensitivity out-
weighed the gain of speciﬁcity with CR compared to
CR+VGPR (Table 1). Sensitivity for CR+VGPR was similar at
days 28 and 56, but speciﬁcity was higher at day 56 than at
day 28. Since CR+VGPR at day 56 still had a 26% false-positive
rate (i.e., 74% speciﬁcity), we evaluated response deﬁnitions
that incorporated an upper limit of the steroid dose as an
additional criterion of success (Figure 1). As shown by the
averages, sensitivity and speciﬁcity showed a balanced trade-
off at prednisone limits between 2.0 and 0.5 mg/kg/day, but
loss of sensitivity outweighed the gain of speciﬁcity at limits
below0.5mg/kg/day. Incorporation of prednisone doses0.5
mg/kg/day in the CR+VGPR endpoint deﬁnition at day 56
decreased the false-positive rate to 15%. When recurrent
malignancy was excluded from the deﬁnition of failure after
day 56, this endpoint had a false-positive rate of only 4%.
Conclusion: Our results support the use of CR+VGPR with an
upper limit of the steroid dose at day 56 as the short-term
response endpoint for acute GVHD treatment trials.Figure 1.
